We are called Molecular Partners because we believe that it is only through strong collaborations that we can fully realize the potential of DARPin® therapeutics for patients.
We aim to collaborate with selected partners that share our drive and commitment to speed the discovery and development of breakthrough therapies to maximize the benefit for patients. Depending on the field, the DARPin® asset, the medical problem, the potential partner’s needs and the collaboration set-up, we customize the ideal deal structure and strive for a fast and nimble decision-making during the process from idea generation to signing a partnership agreement.
To date, Molecular Partners has received combined upfront and milestone payments of approximately CHF 250 million in connection with its agreements with its partners. The company is further eligible to potentially receive additional success-based payments, including up to approximately CHF 1.5 billion in aggregate development, regulatory and sales milestones, and tiered royalties for future product sales.
In 2011, we licensed our lead asset, MP0112 — now called abicipar — to Allergan. The collaboration was expanded in 2012, when Molecular Partners and Allergan signed two new agreements to discover, develop and commercialize proprietary DARPin® therapeutic candidates for the treatment of serious ophthalmic diseases.
In 2018 Allergan exercised its latest option upon which Molecular Partners granted Allergan an exclusive license to the selected multi-DARPin® product candidates for use in ophthalmology.
In 2018, we entered into a collaboration with AstraZeneca on Molecular Partners’ ongoing oncology clinical study with MP0250 in EGFR-mutated Non-Small Cell Lung Cancer. Under the agreement, AstraZeneca provides us osimertinib (Tagrisso®) for free, while all commercial rights for MP0250 reside with Molecular Partners.
In 2018, we entered into a collaboration and license agreement with Amgen for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator).
Under the terms of the agreement, Amgen obtains exclusive global development and commercial rights for MP0310. The parties will jointly evaluate MP0310 in combination with Amgen’s oncology pipeline products, including its investigational BiTE®(bispecific T cell engager) molecules. Under the collaboration, Molecular Partners retains certain rights to develop and commercialize its proprietary DARPin® pipeline products in combination with MP0310.
In 2019, Molecular Partners initiated a research project to explore DARPin® molecules targeting peptide-MHC complexes which is supported by Gilead. The ability to target peptide-MHC complexes with DARPin® molecules has the potential to open the target space significantly, as these targets have been notoriously difficult to address with antibody-based approaches.